CTOs on the Move

Neuros Medical

www.neurosmedical.com

 
Neuros Medical, a Cleveland, Ohio based neurostimulation company, is focused on developing proprietary neurostimulation therapies for unmet needs to patients worldwide.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Zi-Ping Fang
Chief Technology Officer Profile

Funding

Neuros Medical raised $20M on 08/07/2017
Neuros Medical raised $38.5M on 01/07/2021

Similar Companies

Liquidia Technologies

Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.

Lexington Regional Health Center

At Lexington Regional Health Center, we are redefining health care. By embracing a truly patient-centered care model, we focus on you and your family`s needs. From urgent care and 24-hour emergency services, to radiology and physical therapy, we are here for you. Walking through our doors, you`ll feel right at home, because you are. Between detection and prevention, therapy and recovery, diagnosis and treatment; in the middle of it all, Lexington Regional is your health center.

ParaTechs

ParaTechs is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verona Pharma

Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Juventas Therapeutics

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.